Therapy Area topics
Cardiovascular
Bridgebio finally gets its cardiomyopathy win
A convincing hit puts approval, and potentially partnerships, on the table.
Central Nervous System
Biogen hopes to bridge the gap with $7.3bn Reata buy
Biogen’s acquisition of rare neurological disease player Reata provides a much needed near-term sales lift, but at a price.
Diabetes
Spotlight – Nash in 2023 and beyond
The mid-stage Nash pipeline plays host to mechanisms both evidence-backed and unproven, with plenty of data on the horizon.
Stock market strife subsides in second quarter
But large gains for some big pharma players flatter the overall figures.
Digital Health
Sofinnova goes digital
The promise of fast timelines and early revenues lure a new investor into digital medicine.
ESC 2022 – Preventicus gets halfway there
Improving atrial fibrillation diagnosis is one thing; improving outcomes another.
Better Therapeutics banks on data and partnerships
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Respiratory
Go or no go? Decision day looms for Eisai and Biogen
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Various
Pharma finds a way to gain weight
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.